Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    AGBA

    MCap

    USD221m

    Last close

    USD2.97

    ▲ 0.47 (18.80%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Basilea Pharmaceutica (SIX: BSLN)

Last close As at 23/04/2024

CHF41.25

▲ 0.35 (0.86%)

Market capitalisation

CHF541m

Basilea Pharmaceutica is focused on treating infectious diseases; marketed products are Cresemba (antifungal) and Zevtera (anti-MRSA broad-spectrum antibiotic). In late 2023, it expanded its pipeline to include BAL2062 (antifungal), tonabacase (antibiotic) and Phase III-ready fosmanogepix (antifungal).

There is an ever-increasing need for therapeutic agents that are efficacious against drug-resistant strains of bacteria (eg MRSA) or fungi. Hence the opportunities for Zevtera and Cresemba could be significant.

Latest Insights

View More

Healthcare | Update

Basilea Pharmaceutica — Need for innovation against severe infections

Healthcare | Flash note

Basilea Pharmaceutica — CARB-X grant for preclinical programs

Healthcare | Update

Basilea Pharmaceutica — Zevtera crosses key US regulatory hurdle

Healthcare | Flash note

Basilea Pharmaceutica — Strong Cresemba traction triggers milestone payment
misael-moreno-fN6K30xtiKE-unsplash-Basilea
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Associate analyst

Key Management

  • Adesh Kaul

    CFO

  • David Veitch

    CEO

  • Dung Tran

    Investor relations coordinator

Balance Sheet

Forecast net debt (CHFm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 11.9 22.0 (6.7)
Relative 13.7 18.6 (6.7)
52 week high/low CHF48.6/CHF32.2

Financials

At its recent capital markets day (CMD) and with the support of key opinion leaders, Basilea highlighted the rising need for innovative therapies to address serious fungal and bacterial infections. It continues to make advancements in this specialised segment through the development of opportunistic acquisitions leveraging its anti-infective expertise. Its growth initiatives remain funded through the traction of its commercialised products, Cresemba and Zevtera. FY24 key strategic priorities include the US commercial launch of antibacterial Zevtera and Phase III trial initiation of first-in-class, broad-spectrum antifungal fosmanogepix.

Y/E Dec Revenue (CHFm) EBITDA (CHFm) PBT (CHFm) EPS (CHFc) P/E (x) P/CF (x)
2022A 147.8 19.6 12.3 104.10 39.6 N/A
2023A 157.6 20.8 10.8 89.66 46.0 N/A
2024E 187.2 34.0 28.0 233.65 17.7 N/A
2025E 209.1 37.9 32.3 269.24 15.3 N/A

Research

Flash note

Healthcare

Basilea Pharmaceutica — CARB-X grant for preclinical programs

Update

Healthcare

Basilea Pharmaceutica — Zevtera crosses key US regulatory hurdle

Healthcare

Update

Basilea Pharmaceutica — Need for innovation against severe infections
View All

Further insights

insight

Healthcare

Antibiotic resistance

insight

Healthcare

Antibiotics

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

sromanoff@edisongroup.com 020 3077 5700
Read latest

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free